Janssen has revealed updated results from the Phase III MAGNITUDE study, which show that a combination therapy including niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, slowed prostate cancer progression. The drug was investigated in combination with abiraterone acetate plus prednisone (AAP) in patients with metastatic castration-resistant prostate… Read More
Indee Labs and GenScript have formed a research collaboration with the aim to develop a DNA knock-in kit for Hydropore to enable large transgene inserts above the 5kb limit for AAV. As part of the collaboration, GenScript will provide a variety of single-strand and double-strand (ssDNA and… Read More
A new multi-year strategic partnership between M2GEN and Zephyr AI will leverage clinicogenomic data, bioinformatics, and artificial intelligence to accelerate drug discovery and expanded use cases for oncology treatments. In this partnership, M2GEN will license its real-world data set (RWD) to Zephyr AI, while Zephyr AI will… Read More
Aera Therapeutics has launched with a vision to “unlock the potential of genetic medicines across a wide range of modalities and therapeutic areas”. The company’s delivery platform is based on research conducted in the laboratory of scientific founder Feng Zhang and aims to address the limitations of… Read More
A collaboration between Automata and the Advanced Sequencing Facility (ASF) at The Francis Crick Institute hopes to unlock the power of integrated automation for genomics sample preparation. Genomics sample preparation workflows are ideally suited for automation given the need for robustness and scalability. The teams… Read More
Listen to this article on the DDW Podcast: Dr Stephen Barat, Senior Vice President and Therapeutics Division Head at HTG Molecular Diagnostics tells DDW how transcriptomics is driving drug discovery and precision medicines. DDW: Could you explain the process of transcriptomics? SB: Transcriptomics is the study… Read More
The first and only treatment specifically indicated for patients with ESR1 mutations in ER+, HER2- advanced or metastatic breast cancer has been approved in the US. The Food and Drug Administration (FDA) has approved Orserdu (elacestrant) for the treatment of postmenopausal women or adult men, with ER+,… Read More
DDW Editor Reece Armstrong takes a look at the pharmaceutical research and development market in 2023 and asks key opinion leaders what challenges and trends will emerge throughout the year. The Market After over two years of the Covid-19 pandemic, 2022 year was somewhat of a return to… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. The focus has been on immunotherapy and genetics this week, with exciting… Read More
News round-up for 12-16 December by DDW Digital Content Editor Diana Spencer. The focus has been on immunotherapy and genetics this week, with exciting developments in the treatment of multiple myeloma, atopic dermatitis, Alzheimer’s, late-stage melanoma and acute myeloid leukaemia. The top stories: … Read More
Researchers have identified the genetic links between muscle atrophy and two types of myosin, paving the way for a new disease model for scientific research and potential new treatments. The synergistic action of the muscle proteins myosin and actin enables skeletal muscle movements. The skeletal muscle myosin… Read More
PrecisionLife and Ono Pharmaceutical have agreed a multi-target discovery and validation partnership. The R&D collaboration will leverage PrecisionLife’s combinatorial analytics-generated insights to identify novel therapeutic targets and patient stratification biomarkers in central nervous system (CNS) disorders for development by Ono. PrecisionLife analyses multi-modal datasets including… Read More
As gene editing technologies like CRISPR progress toward clinical study, researchers must continue to advance new approaches and address inherent challenges, explains Jon Chesnut, PhD, Senior Director, Cell Biology R&D, Thermo Fisher Scientific. Gene editing tools such as zinc finger nucleases, transcription activator-like effector nucleases (TALEN) and clustered regularly interspaced… Read More
Japanese researchers propose using RNA interference for correcting a mistake in the genetic code of patients with Fukuyama muscular dystrophy. Fukuyama congenital muscular dystrophy (FCMD) is the second most common form of childhood muscular dystrophy in Japan. The disease manifests itself in the form of a severe… Read More
DDW highlights the most interesting global news and comments within the drug discovery and development sector this month. Everyone enjoys a good news story and the drug discovery and development sector is no exception. Seeing tangible results of drug efficacy or therapeutics programmes can take years so it… Read More
The fifth CRISPR in Drug Discovery: From Targets to Therapeutics meeting will be held face to face In Oxford on February 7-8, 2023. The meeting will focus on the application of genome engineering in identification of novel drug targets through large-scale CRISPR based functional genomics studies, developing advanced cellular… Read More
